INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 169 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $716,967 | +1.9% | 13,764 | +23.9% | 0.00% | 0.0% |
| Q2 2023 | $703,675 | +23.3% | 11,113 | +5.5% | 0.00% | 0.0% |
| Q1 2023 | $570,524 | -1.9% | 10,536 | -4.2% | 0.00% | 0.0% |
| Q4 2022 | $581,855 | +11.9% | 10,995 | -1.6% | 0.00% | 0.0% |
| Q3 2022 | $520,000 | -18.5% | 11,171 | 0.0% | 0.00% | -25.0% |
| Q2 2022 | $638,000 | -12.6% | 11,171 | -6.4% | 0.00% | 0.0% |
| Q1 2022 | $730,000 | +20.9% | 11,931 | +3.4% | 0.00% | +33.3% |
| Q4 2021 | $604,000 | +84.1% | 11,535 | +30.9% | 0.00% | +50.0% |
| Q3 2021 | $328,000 | -8.4% | 8,811 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $358,000 | +7.8% | 8,773 | -10.3% | 0.00% | 0.0% |
| Q1 2021 | $332,000 | +12.2% | 9,781 | +5.2% | 0.00% | 0.0% |
| Q4 2020 | $296,000 | +52.6% | 9,296 | +23.0% | 0.00% | +100.0% |
| Q3 2020 | $194,000 | +19.8% | 7,555 | +19.7% | 0.00% | 0.0% |
| Q2 2020 | $162,000 | +125.0% | 6,310 | +33.9% | 0.00% | 0.0% |
| Q1 2020 | $72,000 | -21.7% | 4,713 | +76.5% | 0.00% | 0.0% |
| Q4 2019 | $92,000 | +360.0% | 2,671 | 0.0% | 0.00% | – |
| Q3 2019 | $20,000 | -42.9% | 2,671 | 0.0% | 0.00% | – |
| Q2 2019 | $35,000 | +6.1% | 2,671 | 0.0% | 0.00% | – |
| Q1 2019 | $33,000 | +10.0% | 2,671 | 0.0% | 0.00% | – |
| Q4 2018 | $30,000 | -48.3% | 2,671 | 0.0% | 0.00% | – |
| Q3 2018 | $58,000 | +45.0% | 2,671 | +17.8% | 0.00% | – |
| Q2 2018 | $40,000 | -16.7% | 2,267 | 0.0% | 0.00% | – |
| Q1 2018 | $48,000 | +45.5% | 2,267 | 0.0% | 0.00% | – |
| Q4 2017 | $33,000 | +120.0% | 2,267 | +142.2% | 0.00% | – |
| Q3 2017 | $15,000 | +25.0% | 936 | 0.0% | 0.00% | – |
| Q2 2017 | $12,000 | -20.0% | 936 | 0.0% | 0.00% | – |
| Q1 2017 | $15,000 | +7.1% | 936 | 0.0% | 0.00% | – |
| Q4 2016 | $14,000 | 0.0% | 936 | 0.0% | 0.00% | – |
| Q3 2016 | $14,000 | -54.8% | 936 | +18.0% | 0.00% | – |
| Q2 2016 | $31,000 | +40.9% | 793 | 0.0% | 0.00% | – |
| Q1 2016 | $22,000 | -48.8% | 793 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $43,000 | +168.8% | 793 | +103.3% | 0.00% | – |
| Q3 2015 | $16,000 | +33.3% | 390 | 0.0% | 0.00% | – |
| Q2 2015 | $12,000 | – | 390 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |